Pancreatic cancer drug duo shows durable responses, advancing to Phase 3
A two-drug combo of Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib produced durable responses in the large majority of pancreatic cancer patients in an early-stage trial, prompting Tango to advance the approach to a Phase 3 study.